GSK “Dear Health Care Provider” Letter Cites Rosiglitazone Fracture Risk In Women
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA MedWatch alert issued Feb. 20 notes there were “significantly more” fractures in women taking rosiglitazone in the ADOPT trial.